You are here: Industry Insights > Merck

News List

Eisai, Merck’s Drug Combo Approved for Advanced Endometrial Cancer contractpharma
July 26, 2021
LENVIMA plus KEYTRUDA demonstrates improvements in overall survival, reducing the risk of death by 32%, and progression-free survival by 40%.
Merck gets US FDA nod of adult pneumococcal 15-valent conjugate vaccine expresspharma
July 19, 2021
The US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) is expected to meet in October to discuss and make recommendations on the use of VAXNEUVANCE in adults.
Merck’s MET inhibitor tepotinib gains positive opinion from MHRA pharmatimes
July 16, 2021
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued a positive scientific opinion for Merck’s tepotinib for the treatment of advanced non-small cell lung cancer (NSCLC) with METex14 skipping alterations.
Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology & Infec drugs
July 16, 2021
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced today the presentation of previously announced Phase 2 interim results from two Phase 2/3 clinical trials (MOVe-OUT and MOVe-IN) of molnupiravir
Merck Partners with Innervia Bioelectronics americanpharmaceuticalreview
July 09, 2021
Merck has announced a second collaboration agreement in its Bioelectronics innovation field with Innervia Bioelectronics.
Merck Provides Update on KEYTRUDA® Indication in Third-Line Gastric Cancer americanpharmaceuticalreview
July 05, 2021
Merck announced plans to withdraw the U.S. accelerated approval indication for KEYTRUDA (pembrolizumab) for treatment of patients with recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma, with disease progression on or after two or ...
NGM to Focus on Novel Medicines for Retinal and Cardiovascular and Metabolic Diseases in Collaboration with Merck americanpharmaceuticalreview
July 05, 2021
GM Biopharmaceuticals, Inc. announced that the company has entered into an amended and restated agreement with Merck to extend their ongoing collaboration through March 2024 but with a narrower scope.
Merck Appoints Michael Klobuchar Chief Strategy Officer americanpharmaceuticalreview
June 28, 2021
Merck announced that Michael Klobuchar has been appointed executive vice president and chief strategy officer, a newly created role, effective July 5, 2021.
Global API market to value $300 billion by 2030 europeanpharmaceuticalreview
June 25, 2021
Researchers anticipate the growth of the aging population and rising investment in biologic drugs to promote the expansion of the global active pharmaceutical ingredient (API) market.
Merck’s KEYTRUDA Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Cervical Cancer americanpharmaceuticalreview
June 23, 2021
Merck announced that the pivotal Phase 3 KEYNOTE-826 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-based chemotherapy (paclitaxel plus cisplatin or paclitaxel plus carboplatin) with or without bevacizumab ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page